CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.

Author(s): Gopaluni S, Perzova R, Abbott L, Farah R, Shrimpton A, Hutchison R, Poiesz BJ

Affiliation(s): Department of Medicine, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA.

Publication date & source: 2008-09, Am J Hematol., 83(9):744-6.

Publication type: Case Reports; Research Support, Non-U.S. Gov't; Review

CD8+ cutaneous T-cell lymphoma (CTCL) is a relatively rare subset of the non-Hodgkins lymphomas. Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL. Herein, we report on a patient whose CD8+ CTCL completely responded to treatment with bexarotene. Copyright 2008 Wiley-Liss, Inc.